Anti-Coagulants - New Zealand

New Zealand

Highlights

In 2024, the projected revenue in the Anti-Coagulants market in New Zealand is expected to reach NZD US$41.92m.
This market is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 7.55%, leading to a market volume of NZD US$60.32m by 2029.
When compared globally, United States is forecasted to generate the highest revenue in this market, with an estimated amount of US$16.74bn in 2024.
New Zealand's anti-coagulant market is witnessing a surge in demand due to an aging population and an increase in cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in New Zealand has been steadily growing in recent years as the demand for these drugs increases.

Customer preferences: New Zealand's aging population has been a significant driver for the growth of the Anti-Coagulants market. With an increasing number of elderly people, the risk of developing cardiovascular diseases and blood clots is also increasing. As a result, there has been a growing demand for Anti-Coagulants, which help prevent the formation of blood clots and reduce the risk of heart attacks and strokes.

Trends in the market: One of the major trends in the Anti-Coagulants market in New Zealand is the shift towards newer oral anti-coagulants. These drugs are more effective than traditional warfarin and have fewer side effects. Patients also find them more convenient to use since they do not require regular monitoring, which is necessary with warfarin. As a result, there has been a growing demand for these drugs in New Zealand.

Local special circumstances: New Zealand has a unique healthcare system, which is publicly funded and provides universal healthcare to all citizens. This means that patients have access to Anti-Coagulants regardless of their ability to pay. However, the government has been trying to control the cost of healthcare, which has led to the introduction of generic versions of Anti-Coagulants. This has made these drugs more affordable and accessible to patients.

Underlying macroeconomic factors: New Zealand's economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has allowed the government to invest in new healthcare technologies and drugs, including Anti-Coagulants. The government has also been working to improve the efficiency of the healthcare system, which has led to better patient outcomes and increased access to healthcare services. Overall, the growing economy and the government's commitment to healthcare have created a favorable environment for the growth of the Anti-Coagulants market in New Zealand.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.